+ 0.00
+ 0%
+ 0.00
+ 0%
+ 0.00
+ 0%
+ 0.00
+ 0%
+ 0.00
+ 0%

Aurora Posts Q2 Earnings, Touts 562% Spike In 'International Medical' Cannabis Sales

February 11, 2021 6:45 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Aurora Posts Q2 Earnings, Touts 562% Spike In 'International Medical' Cannabis Sales

Aurora Cannabis (NYSE:ACB) released its second-quarter fiscal 2021 earnings report Thursday afternoon. Here's what we learned:

  • Total cannabis net revenue hovered $70.3 million, excluding provisions of $2.7 million
  • That's up 11% over the second quarter of 2020
  • Medical cannabis net revenue reached $38.9 million — up 42% versus the second quarter of 2020
  • That jump was due to a 562% increase in high margin international medical sales
  • Aurora experienced an adjusted EBITDA loss of $12.1 million
  • That's an improvement of $53.1 million over the second quarter of 2020
  • The company reported improved cash use by more than 74% compared to the second quarter of 2020

As of Feb. 10, the Edmonton, Canada-based cannabis producer has about $565 million in cash on hand. To reach profitability, Aurora is expected to partner with "third party government and non-government consumer sales channels."

Long-Term Profitability: The current loss in EBITDA was "triggered by several decisions" Aurora made to bolster long-term profitability. Recall last year when Aurora let go of more than 1200 of its employees in an effort to improve the balance sheet.

Related Link: Analyzing Aurora Cannabis's Unusual Options Activity

The company, under the helm of CEO Miguel Martin, recently closed activities at its Aurora Sun facility and opted to reduce the production at its flagship Aurora Sky facility by 75%.

And last month, Aurora cut sales staff after picking Great North Distributors for its sales representatives in the Canadian recreational cannabis market.

The stock closed down 23% at $14.47 following a big runup earlier in the week.

Courtesy image